SCHEMBL22041087

SCHEMBL22041087

CCCc1nc(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCC(CC(CO)CO)CC4)ccc3OCC)nn12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 20/20 0.75
PDE1A P54750 7/20 0.75
PDE1B Q01064 7/20 0.75
PDE1C Q14123 7/20 0.75
PDE4B Q07343 2/20 0.75
PDE6A P16499 2/20 0.74
PDE2A O00408 1/20 0.74
PDE6D O43924 1/20 0.74
PDE9A O76083 1/20 0.74
CHRM2 P08172 1/20 0.74
ADORA3 P0DMS8 1/20 0.74
PDE6G P18545 1/20 0.74
MAOA P21397 1/20 0.74
PDE4A P27815 1/20 0.74
ADORA1 P30542 1/20 0.74
ADRA1A P35348 1/20 0.74
PDE6B P35913 1/20 0.74
PDE6C P51160 1/20 0.74
SLC6A3 Q01959 1/20 0.74
PDE4C Q08493 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24239381 0.94 PDE5A (0.74) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL21995209 0.93 PDE5A (0.67) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL12823139 0.92 PDE5A (0.80) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL22041434 0.91 PDE5A (0.77) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL28590132 0.91 PDE5A (0.77) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL24239271 0.91 PDE5A (0.77) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL22041049 0.91 PDE5A (0.77) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL21995247 0.91 PDE5A (0.74) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL22041085 0.91 PDE5A (0.74) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL22043075 0.91 PDE5A (0.80) PDE5APDE1APDE1BPDE1CPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220031704-A1 NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2022-02-03 US disclosed
WO-2020109354-A1 NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220031704-A1 NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE9A, PDE5A, PDE2A PDE5A 2/4885PDE1A 26/4885PDE1B 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.